Ocuphire Pharma Investor Presentation Deck
7
Efficacy Endpoints: % of Subjects ≥ 15 Letter DCNVA Gain Across Timepoints
Nyxol + LDP had Strong Response with ≥ 15 Letter Near Gain from 30 Minutes to 6 Hours
Percent of Subjects (%)
70%
60%
50%
40%
30%
20%
10%
0%
Percent of Subjects with ≥ 15 Letters Binocular Photopic DCNVA Improvement from Baseline
33% Placebo Adjusted
Response
p=0.003
Nyxol alone effect
(~12 hr data)
p=0.09
33%
16%
0
Rapid onset
of efficacy
p=<0.0001
61%
14%
VEGA-1 Phase 2 Trial
0.5
28%
1
61%
Primary Endpoint
p=<0.0001
63%
Placebo (n=43)
16%
2
Time (Hours)
p=0.02
47%
21%
Nyxol+LDP (n=43)
3
p=0.02
21%
4
47%
Durable benefit
over 6 hours
p=0.06
37%
19%
Source: VEGA-1 TLR Table 14.2.1.2 Percent of Subjects with Improvement From Baseline in Photopic DCNVA by Time Point (PP Population). 15 letters is 3 lines.
Ocuphire
PHARMAView entire presentation